Sahay, R.Saresa, H.Changani, M.Kotadia, R.Soni, A.Patel, P.Khanna, K.Kumar, N.Gupta, A.2024-09-242024-09-242023-08Sahay R., Saresa H., Changani M., Kotadia R., Soni A., Patel P., Khanna K., Kumar N., Gupta A.. Determination of the bioavailability and biodistribution of a single dose of oral cholecalciferol/Calcirol® soft gelatin capsule by pharmacoscintigraphy- CalSci study. International Journal of Basic & Clinical Pharmacology. 2023 Jul; 12(4): 528-5372319-20032279-0780https://imsear.searo.who.int/handle/123456789/226673Background: It is required to study the bioavailability and biodistribution of specific cholecalciferol formulation before prescribing. Pharmacoscintigraphy is an established radiological-imaging technique that is used to map various drug formulations as they traverses the human body (biodistribution) in real-time. We evaluated the bioavailability and biodistribution pattern, transit time, and gastrointestinal clearance of a single dose of Calcirol® soft gelatin capsule 60,000 IU [an oral cholecalciferol (vitamin D) formulation] using pharmacoscintigraphy. Methods: Six male healthy adult volunteers were administered a single oral dose of Calcirol® soft gelatin capsule labelled with technetium-99m. Post-dosing, serial venous blood samples were collected till day 27 for the estimation of the plasma levels of 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol levels. Different pharmacokinetic parameters were calculated. Sequential static gamma imaging was performed to evaluate the biodistribution of Calcirol® soft gelatin capsule. Descriptive statistics was used. Various pharmacokinetic parameters were calculated from the concentration-time curves. Statistical analysis was carried out using Student’s t-test. Suitable multivariate analysis was performed based on the distribution of data. All statistical analyses were performed using SAS® Software (v 9.4). Results: The overall absorption of Calcirol® soft gelatin capsule was 93.23%, which was fully from the small intestine. It led to achieving a sufficient level of 25-hydroxycholecalciferol (>60 ng/ml) within 6 hours of oral intake. The levels of plasma 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol increased (maximum around 6 and 18 days, respectively). The small intestinal residence time was around 16 hours. No adverse event was noted. Conclusions: This was the first pharmacoscintigraphy study in the world which demonstrated the favourable bio-distribution of the Calcirol softgels supporting its role in vitamin D supplementation.BioavailabilityBiodistributionCalcirol®CholecalciferolPharmacokineticsPharmacoscintigraphyJournal ArticleIndiaSahay's Endocrine and Diabetes Centre, Ameerpet, Hyderabad, IndiaCadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India|Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India|Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India|Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India|Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, IndiaDepartment of Pharmacy, Lloyd Institute of Management and Technology, Greater Noida, Uttar Pradesh, IndiaHypotho Research Limited, Delhi, IndiaDepartment of Pharmacy, Lloyd Institute of Management and Technology, Greater Noida, Uttar Pradesh, India